RT Journal Article
SR Electronic
T1 Serum Levels of Soluble Syndecan-1 in Hodgkin's Lymphoma
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 4743
OP 4746
VO 25
IS 6C
A1 THEODOROS P. VASSILAKOPOULOS
A1 MARIE-CHRISTINE KYRTSONIS
A1 ARGIROULA PAPADOGIANNIS
A1 GIANPAOLO NADALI
A1 MARIA K. ANGELOPOULOU
A1 TATIANA TZENOU
A1 MARIA N. DIMOPOULOU
A1 MARINA P. SIAKANTARIS
A1 FLORA N. KONTOPIDOU
A1 CHRISTINA KALPADAKIS
A1 STYLIANI I. KOKORIS
A1 EVANGELIA M. DIMITRIADOU
A1 PANAYIOTIS TSAFTARIDIS
A1 GIOVANNI PIZZOLO
A1 GERASSIMOS A. PANGALIS
YR 2005
UL http://ar.iiarjournals.org/content/25/6C/4743.abstract
AB Background: Syndecan-1 (CD138) is expressed by the Hodgkin-Reed-Sternberg (HRS) cells of classic Hodgkin's lymphoma (cHL), but not in nodular lymphocyte-predominant HL. Syndecan-1 may be involved in the interaction between HRS cells and the cellular and stromal microenvironment typical of nodular sclerosing HL. Patients and Methods: Serum levels of soluble syndecan-1 were determined by ELISA in 66 patients with HL and 14 age- and sex-matched healthy individuals. Results: The levels of syndecan-1 were higher in HL patients than controls (100.2±35.9 ng/ml vs. 67.9±24.5 ng/ml, p<0.001). They marginally correlated with advanced age (p=0.06), male gender (p=0.07) and consequently high IPS (p=0.01), but did not correlate with markers of tumor burden and prognosis, including serum interleukin-10 and soluble CD30. At 6 years, failure-free survival was 70±9% vs. 50±11% (p=0.32) for patients with serum soluble syndecan-1 levels above or below the observed median value of 91 ng/ml. Conclusion: The serum levels of syndecan-1 were elevated in patients with HL, but were not strongly correlated with other potential prognostic factors. Their effect on prognosis deserves further evaluation. Copyright© 2005 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved